Skip to main content
. 2014 Feb 18;170(2):445–453. doi: 10.1111/bjd.12695

Table 3.

Treatment-emergent adverse events at the injection site (incidence ≥ 10%)

Adverse event by injection-site category Incidence (%)
Placebo ATX-101 1 mg cm−2 ATX-101 2 mg cm−2
Pain including burning 25·4 77·3 80·2
Swelling including oedema 30·3 65·5 66·1
Bruising including bleeding 41·0 55·5 53·7
Numbness 2·5 47·9 51·2
Erythema 23·0 38·7 37·2
Induration including fibrosis 2·5 18·5 26·4